admin
● ENTOD aided Ukraine with medical supplies amidst the Russia-Ukraine war crisis
● ENTOD launched its “HyTek” ophthalmic super speciality surgical division
● The company is planning to hire over 500 additional field-based sales workforce this financial year
● ENTOD launched its medical & cosmetics derma division “ENTOD Beauty London” in collaboration with its international research partners.”
Mumbai, July 09, 2022:
Established in the year 1977 by the late Mr G V Masurkar, ENTOD Pharmaceuticals will be celebrating its foundation day on 11th July on the occasion of the 100th birth anniversary of its founder. A visionary leader in the Indian pharmaceutical industry, Mr G V Masurkar’s continued passion for quality, research and innovation has propelled ENTOD Pharmaceuticals into a global brand with specialized expertise in the ENT, Ophthalmic and Dermatology medicine fields. Not to forget, he was also the man and brains behind the popular Indian paracetamol brand “CROCIN” which presently is a household painkiller brand in India.
ENTOD Pharmaceuticals will mark its 45th year in business, an exciting milestone for the company, its employees, and customers all over the world. ENTOD started as a contract manufacturer for sterile products (eye drops and injections) by establishing two manufacturing units on the outskirts of Mumbai.
However, it was during the late 1990s that it optimised its business model and started its own marketing & sales activities with a focus on developing and selling its own branded medicines. In early 2000, ENTOD massively upgraded its R&D facilities, quality systems and company protocols to increase its product range, marketing and sales activities and field-based representatives in order to increase its turnover.
Thereafter it continued to make impressive and consistent progress in both the Indian domestic as well as export markets and created a global name for itself in the ophthalmic, ENT & dermatology segments.
Recently, ENTOD received an approval from the DCGI to start phase 3 clinical trials for 0.05% low-dose atropine eye drops. If successful it will be the first one to launch these eye drops in India and in the world. ENTOD has also aided Ukraine with medical supplies amidst the Russia-Ukraine war crisis.
The company has also recently ventured into the ophthalmic surgical market through the launch of its super speciality surgical “HYTEK” division in order to further strengthen its position in the ophthalmology market. ENTOD Beauty London is another medical & cosmetic derma division initiative by ENTOD in collaboration with its international partners.
In the last 2 years the company has significantly expanded its product based with innovative technology-driven products including the launch of its nanotechnology-based under eye gel serum “Eyecirque” in early 2022.
Speaking on the occasion of the company’s foundation day, Nikkhil K Masurkar, Executive Director of ENTOD Pharmaceuticals said “Today ENTOD Pharmaceuticals is part of the ENTOD INTERNATIONAL Group together with our other sister concern research companies which have grown into an international research-based pharmaceutical organisation with over 4 decades of pharmaceutical expertise in Ophthalmology, ENT and Dermatology medicine.
In 2010, we started our UK and international operations that allowed us access to regulated markets, and considerably increased our export business. Since then the company has gone from strength to strength with a global reach spanning 55 countries worldwide including the UK & Europe. All these achievements have been made possible through the hard work and perseverance of all our employees, teams and workers. Thanks to everyone who supports us, each and every day. We couldn’t do it without you, and we are extremely grateful”.
“Globally, ENTOD has over 250 products in its portfolio, a global field force of over 1000 and highly experienced Quality Assurance, Production and R&D teams. Our quality systems are now certified in Europe and our manufacturing quality standards adhere to international GMP norms. Over the coming years, we are planning to increase our field strength by recruiting more employees and expand further into ophthalmic surgical & medical / cosmetic dermatology segments. This will further enable us to establish our stronghold in the domestic and international markets” he added.
“It’s been a long journey for ENTOD and it wouldn’t have been possible without the visionary approach of our founder and the immense contributions of all our employees. Being in the industry for more than four decades has taught us that innovation is the key not only to growth but also to strengthening our position in the market.
As part of our medium to long-term expansion plans, we are planning to enter the respiratory segment in the coming years too. Investment in R&D and new product development has already begun for respiratory products and we hope to start commercial activities in this segment by early 2024” said Mrs Anjula Masurkar, the clinical director of ENTOD Pharmaceuticals.
healthysoch
HealthySoch
